Statement by the Ethics Advisory Board of Advanced Cell Technology, Inc.

The Advanced Cell Technology Ethics Advisory Board (EAB) exists to provide independent and informed advice to the leadership and researchers of Advanced Cell Technology (ACT) on matters of ethical importance raised by company activities and research programs. Members of the board are independent scholars or professionals with no financial ties to ACT.

The ACT EAB has been kept fully informed of the research to be reported in the July edition of Nature Biotechnology on the generation of immunologically compatible tissues using nuclear transplantation. We believe that this research represents an important milestone in demonstrating the feasibility of new therapies of tissue and organ repair that could benefit millions of people.

We wish to emphasize that this research, which was done under the supervision and ethical review of a separate Animal Care and Use Committee, differs in one important respect from the kind of human therapeutic cloning research undertaken by ACT and approved by the EAB. It uses cloned bovine fetuses of 5-6 weeks' gestational age. The ethical rules for humans and livestock animals are different. While the reported research is appropriate in animal studies, it should never be done in human beings. Strict guidelines established by the EAB in conformity with international standards for human embryo research prohibit the culturing of any human embryo in vitro for more than 14 days of development and prohibit any attempt to implant an embryo resulting from nuclear transplantation into a uterus. The longer period of development allowed in the bovine experiments was needed because bovine embryonic stem (ES) cells capable of differentiating into specified tissue have not yet been isolated. However, human and primate ES cells taken from blastocysts have been successfully differentiated in vitro into derivatives of all cell types.

The members of the ACT EAB support legislation proposed by Senators Specter, Feinstein, Hatch, Kenned

Contact: Ronald M. Green, Ph.D.
Advanced Cell Technology

Page: 1 2

Related biology news :

1. Statement by Stanford President John Hennessy on Jim Clark`s stem cell announcement
2. Statement from Dr. Claude Lenfant on discovery of the gene for primary pulmonary hypertension
3. Statement by APA President Allan Tasman, M.D., on the Surgeon Generals Report on Mental Health
4. Statement on discovery of the gene for narcolepsy in dogs
5. Statement Of The DFG Concerning "Questions Of Human Embryonic Stem Cells"
6. AHA Issues Scientific Statement On Infective Endocarditis
7. Environmental Impact Statements Need To Be Made Easier To Decipher
8. National Academies Advisory: Sept. 18-19 Nanotechnology Conference
9. National Academies Advisory: June 25 UN public briefing on agriculture in Africa
10. Media Advisory-GSA 2003 Annual Meeting
11. Media Advisory

Post Your Comments:

(Date:5/1/2020)... ... April 30, 2020 , ... USARAD Holdings Inc., the leading ... VC firms announces an official launch of CareDoctors.com. In an effort to help ... experience by offering live video consultations with board certified physicians in all specialties ...
(Date:5/1/2020)... ... April 30, 2020 , ... InBios International Inc., ... it had been awarded a contract from the Biomedical Advanced Research and Development ... Response at the U.S. Department of Health and Human Services, to develop the ...
(Date:4/30/2020)... ... 28, 2020 , ... Pebble Labs USA Inc. , a biotechnology company ... with the mission of improving global food security, announced today that they have been ... in Food- and Ag-Tech ' virtual event, a global initiative to drive innovation in ...
Breaking Biology News(10 mins):
(Date:5/15/2020)... ... May 14, 2020 , ... RoosterBio ... banks and hMSC bioprocess systems, today announced the launch of its product ... vesicles (EVs). RoosterCollect™-EV-CC is the only system designed with hMSC-EV product developers ...
(Date:5/15/2020)... ... 2020 , ... Sentien Biotechnologies, Inc., a clinical-stage biotechnology company developing novel approaches ... Mr. Ganz will continue to lead Sentien’s Board of Directors, a role he has ... Miller and Sentien’s management team. , Mr. Ganz has more than 30 ...
(Date:5/14/2020)... , ... May 13, 2020 , ... ... called Future Lab: Optimizing Workflows in the Life Science Lab . The ... in their lab, from water purification and liquid handling to contamination control. , ...
(Date:5/5/2020)... ... May 04, 2020 , ... ... the life sciences industry, today announced that Informa Training Partners, a life sciences ... name to Red Nucleus Boston, effective immediately. , “The name change solidifies a ...
Breaking Biology Technology:
Cached News: